Cancerous inhibitor of protein phosphatase 2A regulates cisplatin resistance in ovarian cancer
Open accessAbstract
Ovarian cancer is the most aggressive type of gynecological cancer. The cause of the poor survival rate is the development of chemotherapy resistance to platinum-based therapies, including cisplatin. The present study aimed to investigate the mechanism of cancerous inhibitor of protein phosphatase 2A (CIP2A)-induced chemoresistance in ovarian cancer. The present study initially investigated the expression of CIP2A in the ovarian tumor tissue, cisplatin-sensitive SKOV-3 cell line, and cisplatin-resistant ovarian carcinoma SKOV-3CDDP/R cell line. In addition, CIP2A was knocked down using small interference RNA in ovarian cancer cells and the chemosensitivity of these cells was analyzed. The results demonstrated that CIP2A expression was significantly higher in patients with ovarian cancer and in the cisplatin-resistant ovarian carcinoma SKOV-3CDDP/R cell line at the mRNA and protein levels. The proliferation and chemosensitivity were decreased and enhanced, respectively, when CIP2A was knocked down. CIP2A silencing significantly promoted the apoptosis induced by cisplatin in SKOV-3CDDP/R cells, suggesting that CIP2A participated in the cisplatin resistance of ovarian cancer cells and that CIP2A silencing enhanced the apoptosis induced by cisplatin. CIP2A may be considered as a potential candidate for modulating cisplatin therapy in ovarian cancer.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
These results reinforce prior suggestions that CIP2A-deficient tumors may be more responsive to therapy.
“The results also support the earlier findings that CIP2A-deficient tumors could constitute a more therapy sensitive subtype (10,12,13).”
From Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype (2022) · cites this paper as [10]
The Discussion reports that CIP2A depletion increased ovarian cancer cell sensitivity to cisplatin, supporting the suggested link between low CIP2A and treatment sensitivity. The study tested ovarian cancer cell lines, however, not whether CIP2A-deficient tumors constitute a therapy-sensitive subtype or respond better to therapies generally. (LLM, conf=0.85)
Experimental — accuracy not yet measuredIn cultured ovarian cancer cells, CIP2A protects against apoptosis caused by cisplatin.
“CIP2A was recently also shown in cell culture to protect OvCa cells from Cisplatin-induced apoptosis (10), and to associate with stemness features in patient-derived high grade serous cancer (HGSC) cells (11).”
From Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype (2022) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860 · see citing works
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499 · see citing works
Signet-Ring Cell Carcinoma of the Colon: A Case Report and Review of the Literature
Park, P. Y., Goldin, T. A., Chang, J. C. S., Markman, M. M., & Kundranda, M. N. (2015) · Case Reports in Oncology · doi:10.1159/000441772 · Cited by 5,273 · see citing works
Mutation of the mouse klotho gene leads to a syndrome resembling ageing
Kuro-o, M., Matsumura, Y., Aizawa, H., Kawaguchi, H., Suga, T., Utsugi, T., Ohyama, Y., Kurabayashi, M., Kaname, T., Kume, E., et al. (1997) · Nature · doi:10.1038/36285 · Cited by 3,837 · see citing works
Rethinking ovarian cancer: recommendations for improving outcomes
Vaughan, S., Coward, J. I. G., Bast, R. C., Berchuck, A., Berek, J. S., Brenton, J. D., Coukos, G., Crum, C. P., Drapkin, R., Etemadmoghadam, D., et al. (2011) · Nature reviews. Cancer · doi:10.1038/nrc3144 · Cited by 1,470 · see citing works
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677 · see citing works
CIP2A Is Associated with Human Breast Cancer Aggressivity
Côme, C., Laine, A., Chanrion, M., Edgren, H., Mattila, E., Liu, X., Jonkers, J., Ivaska, J., Isola, J., Darbon, J.-M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3283 · Cited by 221 · see citing works
Miller, D. S., Blessing, J. A., Krasner, C. N., Mannel, R. S., Hanjani, P., Pearl, M. L., Waggoner, S. E., & Boardman, C. H. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.2963 · Cited by 186 · see citing works
MYC-Dependent Regulation and Prognostic Role of CIP2A in Gastric Cancer
Khanna, A., Böckelman, C., Hemmes, A., Junttila, M. R., Wiksten, J.-P., Lundin, M., Junnila, S., Murphy, D. J., Evan, G. I., Haglund, C., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp103 · Cited by 185 · see citing works
CIP2A mediates effects of bortezomib on phospho-Akt and apoptosis in hepatocellular carcinoma cells
Chen, K.-F., Liu, C.-Y., Lin, Y.-C., Yu, H.-C., Liu, T.-H., Hou, D.-R., Chen, P.-J., & Cheng, A.-L. (2010) · Oncogene · doi:10.1038/onc.2010.357 · Cited by 152 · see citing works
Li, W., Ge, Z., Liu, C., Liu, Z., Björkholm, M., Jia, J., & Xu, D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4137 · Cited by 142 · see citing works
Self-citationCIP2A is a target of bortezomib in human triple negative breast cancer cells
Tseng, L.-M., Liu, C.-Y., Chang, K.-C., Chu, P.-Y., Shiau, C.-W., & Chen, K.-F. (2012) · Breast Cancer Research · doi:10.1186/bcr3175 · Cited by 122 · see citing works
Overexpression and Small Molecule-Triggered Downregulation of CIP2A in Lung Cancer
Ma, L., Wen, Z.-S., Liu, Z., Hu, Z., Ma, J., Chen, X.-Q., Liu, Y.-Q., Pu, J.-X., Xiao, W.-L., Sun, H.-D., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0020159 · Cited by 96 · see citing works
Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients
Capoluongo, E., Ellison, G., López‐Guerrero, J. A., Penault-Llorca, F. M., Ligtenberg, M. J. L., Banerjee, S. N., Singer, C. F., Friedman, E., Markiefka, B., Schirmacher, P., et al. (2017) · Seminars in Oncology · doi:10.1053/j.seminoncol.2017.08.004 · Cited by 96 · see citing works
MKP1/CL100 controls tumor growth and sensitivity to cisplatin in non-small-cell lung cancer
Chattopadhyay, S., Machado-Pinilla, R., Manguán-García, C., Belda-Iniesta, C., Moratilla, C., Cejas, P., Vara, J. Á. F., de Castro-Carpeño, J., Casado, E., Nistal, M., et al. (2006) · Oncogene · doi:10.1038/sj.onc.1209364 · Cited by 96 · see citing works
Increase in CIP2A expression is associated with doxorubicin resistance
Choi, Y. A., Park, J. S., Park, M. Y., Oh, K. S., Lee, M. S., Lim, J.-S., Kim, K. I., Kim, K.-Y., Kwon, J., Yoon, D. Y., et al. (2011) · FEBS Letters · doi:10.1016/j.febslet.2011.01.018 · Cited by 54 · see citing works
Management of recurrent epithelial ovarian cancer.
Vargas-Hernández, V. M., Moreno‐Eutímio, M. A., Acosta‐Altamirano, G., & Vargas-Hernández, V. M. (2014) · PubMed Central · doi:10.3978/j.issn.2227-684x.2013.10.01 · Cited by 53 · see citing works
Yu, H.-C., Hou, D., Liu, C., Lin, C., Shiau, C., Cheng, A., & Chen, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055705 · Cited by 46 · see citing works
Development of erlotinib derivatives as CIP2A-ablating agents independent of EGFR activity
Chen, K., Pao, K., Su, J.-C., Chou, Y.-C., Liu, C., Chen, H.-J., Huang, J., Kim, I., & Shiau, C. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.08.039 · Cited by 38 · see citing works
Regulation of LC3-Dependent Protective Autophagy in Ovarian Cancer Cells by Protein Phosphatase 2A
Yin, X., Zhang, N., & Di, W. J. (2013) · International Journal of Gynecological Cancer · doi:10.1097/igc.0b013e3182892cee · Cited by 25 · see citing works
CIP2A is associated with multidrug resistance in cervical adenocarcinoma by a P-glycoprotein pathway
Liu, J., Wang, M., Zhang, X., Wang, Q., Qi, M., Hu, J., Zhou, Z., Zhang, C., Zhang, W., Zhao, W., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-4032-8 · Cited by 14 · see citing works
A new model of ovarian carcinogenesis may influence early detection strategies
Burger, R. A. (2008) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2008.01.004 · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
PP2A: A Promising Biomarker and Therapeutic Target in Endometrial Cancer
Remmerie, M., & Janssens, V. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00462 · Cited by 59 · see citing works
The voltage-gated sodium channel Nav1.7 associated with endometrial cancer
Liu, J., Tan, H., Yang, W., Yao, S., & Hong, L. (2019) · Journal of Cancer · doi:10.7150/jca.31544 · Cited by 27 · see citing works
Shen, F., Chen, Y., Chen, L., Qin, J., Li, Z., & Xu, J. (2019) · The Anatomical Record · doi:10.1002/ar.24229 · Cited by 13 · see citing works
RetractedCytotoxicity of Standardized Curcuminoids Mixture against Epithelial Ovarian Cancer Cell Line SKOV-3
Almosa, H., Al-qriqri, M., Denetiu, I., Baghdadi, M. A., Alkhaled, M., Alhosin, M., Aldajani, W. A., Zamzami, M. A., Üçışık, M. H., & Damiati, S. (2020) · Scientia Pharmaceutica · doi:10.3390/scipharm88010011 · Cited by 12 · see citing works
Emerging roles of the CIP2A–TopBP1 complex in genome integrity
Ummethum, H., Li, J., Lisby, M., & Oestergaard, V. H. (2023) · NAR Cancer · doi:10.1093/narcan/zcad052 · Cited by 7 · see citing works
Data mining analysis of the PP2A cell cycle axis in mesothelioma patients
Pippa, R., Boffo, S., Odero, M. D., & Giordano, A. (2019) · Journal of Cellular Physiology · doi:10.1002/jcp.29414 · Cited by 6 · see citing works
Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype
Cvrljevic, A. N., Butt, U., Huhtinen, K., Grönroos, T. J., Böckelman, C., Lassus, H., Butzow, R., Haglund, C., Kaipio, K., Arsiola, T., et al. (2022) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-21-0622 · Cited by 5 · see citing works
Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype
Cvrljevic, A. N., Butt, U., Huhtinen, K., Grönroos, T. J., Böckelman, C., Lassus, H., Kaipio, K., Arsiola, T., Laajala, T. D., Connolly, D. C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.03.31.437804 · Cited by 5 · see citing works
Saleh, M., Zam, Z. Z., & Hofer, T. S. (2020) · Journal of Molecular Liquids · doi:10.1016/j.molliq.2020.114612
Cvrljevic, A. N., Butt, U., Huhtinen, K., Grönroos, T. J., Böckelman, C., Lassus, H. J., Bützow, R. C., Haglund, C. H., Kaipio, K., Arsiola, T., et al. (2023) · doi:10.1158/1535-7163.c.6543912.v1
- Authors
- Li, W., Zhang, H., Yang, L., & Wang, Y.
- Affiliations
- Jining Medical University (CN)
- Affiliated Hospital of Jining Medical University (CN)
- Venue
- Oncology Letters
- Publisher
- Spandidos Publications
- Published
- 2018-11-01
- Volume
- 17
- Issue
- 1
- Pages
- 1211-1216
- ISSN
- 1792-1074 (ISSN-L)
- 1792-1082
- PMC
- PMC6313081
- OpenAlex
- W2898899650
- Cited by
- 9
- References
- 22
- Citations by year
- 2023: 2 · 2022: 1 · 2020: 2 · 2019: 4
- FWCI
- 1.61
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Oncology Letters (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian cancer diagnosis and treatment
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Keywords
- CIP2A, cisplatin resistance, ovarian cancer, chemoresistance, apoptosis, protein phosphatase 2A, SKOV3 cells, gene silencing, cell proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
